NE NEWS SERVICE
AHMEDABAD, JULY 6
Drug firm Zydus Cadila on Monday said it has received approval from Mexico”s regulatory authority Cofepris to test one of its lead research candidate Desidustat in the management of COVID-19.
“Clinical and regulatory development of Desidustat in COVID-19 is being executed in Mexico by Avant Santé Research Center S.A. de C.V., a leading contract research organisation headquartered in Monterrey, Mexico,” Cadila Healthcare said in a regulatory filing.
The company said it will conduct a study to evaluate the efficacy and safety of Desidustat tablets for the management of COVID-19 patients.
“As a part of the study, 100 mg tablets of Desidustat will be administered for a period of 14 days along with recommended standard care during the trial,” the company added.
Zydus Cadila Chairman Pankaj R Patel said, “At Zydus, we have been stepping up our efforts to fight the COVID-19 pandemic through therapeutic drugs, diagnostics, and vaccines. With Desidustat we will study a novel approach for management of COVID-19″.
Zydus had initiated two phase-III trials of Desidustat.
Last week, Zydus had received approval from Indian authorities to start human trials for its COVID-19 vaccine contender – the second Indian pharmaceutical firm to get such nod amid a surge in novel coronavirus infections worldwide.
